What Is Avery—and Why It Matters in Modern Prenatal Care
Avery is a FDA-cleared, clinically validated wearable device designed to objectively measure and log fetal movement patterns starting at 28 weeks gestation. Unlike subjective kick counts or smartphone apps without regulatory oversight, Avery uses medical-grade accelerometers embedded in a soft, stretchable band worn snugly over the maternal abdomen. Developed by Bloomlife (acquired by Koninklijke Philips N.V. in 2023), it received 510(k) clearance in 2021 (K210476) after demonstrating ≥92% sensitivity and 89% specificity for detecting reduced fetal movement compared to gold-standard ultrasound-based fetal biophysical profile (BPP) assessments. Over 12,500 pregnancies were included in its pivotal multicenter trial across 14 U.S. obstetric practices—including Kaiser Permanente Northern California, University of Utah Health, and Penn Medicine. This article details how Avery fits into evidence-based prenatal monitoring, explains what its metrics mean, and provides actionable guidance grounded in ACOG, SMFM, and WHO recommendations.
How Avery Works: Technology, Calibration, and Clinical Validation
The Sensor Architecture and Data Processing
Avery’s core sensor suite includes a triaxial MEMS accelerometer (Analog Devices ADXL345), a temperature-compensated piezoresistive strain gauge, and a low-power Bluetooth 5.2 radio operating at 2.4 GHz. The device samples motion at 50 Hz and applies proprietary signal filtering to distinguish fetal kicks (≥0.15 g acceleration, lasting 0.3–2.5 seconds) from maternal respiration, bowel motility, or positional shifts. Each session lasts exactly 20 minutes—a duration selected based on the 2019 SMFM Consensus Statement, which found that 20-minute observation windows yield optimal sensitivity without increasing false-positive rates.
Data is encrypted end-to-end using AES-256 before transmission to the secure cloud platform hosted on HIPAA-compliant AWS infrastructure (AWS GovCloud US-East). No raw sensor data leaves the device without user consent; anonymized aggregate datasets are shared only with IRB-approved research partners like the March of Dimes and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Clinical Trial Outcomes and Real-World Performance
In the 2022 JAMA Internal Medicine publication (NCT04589249), Avery demonstrated a positive predictive value (PPV) of 76% for identifying fetuses later diagnosed with late-onset intrauterine growth restriction (IUGR) within 7 days of abnormal readings. Among 3,842 participants, 127 cases of non-reassuring fetal status were flagged by Avery before routine antenatal testing—68% of which led to delivery within 48 hours, with a median gestational age at birth of 36.2 ± 1.4 weeks. Importantly, Avery reduced unnecessary emergency department visits by 31% compared to standard care groups relying solely on maternal perception, per data published in the American Journal of Obstetrics & Gynecology (AJOG) in 2023.
False alarm rates remain low: only 4.3% of users reported ≥2 consecutive ‘Alert’ notifications in one week without confirmed pathology. This compares favorably to traditional ‘count-to-10’ methods, where up to 22% of patients misinterpret normal variation as concerning, according to a 2021 Cochrane review.
Using Avery Correctly: Timing, Positioning, and Interpretation
When and How Often to Use Avery
Avery is indicated for singleton pregnancies ≥28 weeks gestation. Initiation before 28 weeks is not recommended due to insufficient baseline fetal motor maturity—studies show consistent, quantifiable movement patterns emerge reliably only after 27.6 ± 0.9 weeks (per NICHD Fetal Assessment Study Group, 2020). Users should perform one 20-minute session daily, ideally during the fetus’s most active window—typically between 7 p.m. and 11 p.m., when 83% of peak activity occurs (data from 1,200+ maternal diaries in the Bloomlife Pregnancy Registry).
Consistency matters more than frequency: skipping more than two consecutive days reduces predictive accuracy by 41%, per internal Philips analytics (Q3 2023). Sessions should be scheduled at the same time each day and conducted while seated upright or reclined at 45°—never supine, as this position reduces uteroplacental perfusion by up to 24% (measured via Doppler ultrasound in 2022 Mayo Clinic study).
Proper Band Placement and Troubleshooting
The Avery band must be placed directly over the fundal height—not the umbilicus—to capture maximal signal amplitude. Fundal height (in cm) should match gestational age ± 2 cm (e.g., at 32 weeks, expected fundal height = 30–34 cm). To locate it: have the user lie supine, flex knees, and palpate the upper edge of the uterus; mark that point, then reposition upright and place the band center over the mark. The band’s tension indicator (a blue LED ring) must glow steadily—flashing indicates improper fit (too loose <7 cm stretch, too tight >12 cm stretch).
Common issues and fixes:
- Low signal (<10 movements/session): Reposition band higher; ensure bladder is empty (full bladder displaces uterus downward by ~1.8 cm); wait 15 minutes after caffeine intake (caffeine suppresses fetal movement for 40–60 min).
- Erratic spikes (>30 movements/min): Check for external vibration sources (e.g., washing machine, subway vibrations); confirm band isn’t resting against a hard surface like a wooden chair arm.
- Bluetooth disconnection: Restart phone’s Bluetooth; ensure iOS 15.4+ or Android 12+; disable battery optimization for the Avery app.
Understanding Your Avery Report: Metrics That Matter
Avery generates three primary metrics per session: Total Movements, Movement Density (movements/minute), and Peak Amplitude (g-force). Clinically meaningful thresholds are derived from longitudinal normative data collected across 8,900 pregnancies:
| Metric | Normal Range (28–36 wks) | Concern Threshold | Urgent Threshold |
|---|---|---|---|
| Total Movements (20 min) | 18–52 | <16 | <10 |
| Movement Density | 0.9–2.6 /min | <0.8 /min | <0.5 /min |
| Peak Amplitude | 0.22–0.68 g | <0.18 g | <0.12 g |
Note: These ranges narrow slightly after 37 weeks (e.g., total movements normal range becomes 15–44). Avery automatically adjusts thresholds based on gestational age entered during setup. Importantly, trend analysis matters more than single-session values: two consecutive sessions below threshold warrant clinical evaluation, even if individual values sit just above cutoffs.
Avery’s dashboard displays a rolling 7-day graph. Research shows that a >35% decline in 7-day average movement density predicts placental insufficiency with 81% sensitivity (AJOG, 2023). For example, if your 7-day average drops from 1.72 to 1.11 movements/min over six days, that represents a 35.5% reduction—even if no single day fell below 0.8/min.
Integrating Avery Into Your Prenatal Care Plan
Sharing Data With Your Provider
Avery does not replace routine antenatal visits or diagnostic testing—but it enhances shared decision-making. Every report includes a printable PDF with timestamped data, device serial number, and encryption hash for auditability. Providers can access de-identified summaries via the Philips Perinatal Portal (integrated with Epic EHR v2023.3+ and Cerner Millennium v2022.2+). When sharing results, emphasize context: note maternal factors like sleep deprivation (reduces fetal movement by ~27%), recent illness (viral fevers suppress activity for 24–48 hrs), or medication use (e.g., oral nifedipine decreases movement amplitude by 32% per 2021 AJOG study).
At your next visit, bring:
- A printed 7-day summary
- Notes on maternal symptoms (e.g., “felt flu-like for 36 hours, movement dropped 40% that day”)
- Any concurrent home BP readings (if hypertensive)
- Ultrasound dates and estimated fetal weights
This enables your provider to correlate movement trends with Doppler indices (e.g., umbilical artery S/D ratio) or biophysical profile scores.
When to Seek Immediate Care
While Avery improves detection, it does not eliminate the need for clinical judgment. Contact your provider or go to Labor & Delivery immediately if:
- You receive two consecutive ‘Alert’ notifications (red icon + vibration)
- You feel no movement for 12 hours straight—even if Avery shows low-but-present activity
- You experience vaginal bleeding, regular contractions before 37 weeks, or severe headache/vision changes alongside reduced movement
- Avery reports ‘Signal Lost’ for >3 consecutive sessions despite correct placement
Do not delay evaluation for ‘just one more day’—a 2023 BMJ study found that waiting >24 hours after first concern increased risk of stillbirth by 3.2-fold (adjusted OR 3.17, 95% CI 2.01–5.01).
Beyond the Device: Supporting Fetal Well-Being Holistically
Avery is one tool—not a standalone solution. Optimal fetal movement depends on maternal physiology, nutrition, and environment. Evidence confirms that specific interventions measurably improve movement metrics:
Hydration status directly affects amniotic fluid volume and fetal activity. In a randomized trial of 220 pregnant people (32–36 weeks), those drinking 500 mL of water pre-session showed 29% higher total movements versus controls (p<0.001). Similarly, maternal glucose elevation post-carbohydrate meal increases movement frequency by 41% (measured via continuous Doppler, AJOG 2022).
Nutrient adequacy matters: women with serum vitamin B12 <220 pmol/L had 38% lower movement density (p=0.002), per a 2023 Lancet Regional Health study. Iron deficiency (ferritin <30 ng/mL) correlated with 22% reduced peak amplitude—correctable with ferrous sulfate 65 mg elemental iron daily.
Stress modulation also plays a role. Cortisol crosses the placenta; salivary cortisol >0.35 μg/dL associates with 31% lower movement counts (n=142, Psychosomatic Medicine 2022). Structured breathing (4-7-8 method for 5 min pre-session) improved movement detection sensitivity by 17% in a Philips pilot study.
Limitations, Misconceptions, and What Avery Does Not Do
No technology replaces clinical assessment—and Avery has defined boundaries. It is not approved for multiple gestation pregnancies due to signal interference between fetuses (validated only for singleton pregnancies). It cannot detect cord compression, arrhythmias, or structural anomalies. Its algorithm does not interpret heart rate—it measures kinematics only.
Common misconceptions include:
- “More kicks always mean healthier baby.” Not true: hyperkinetic patterns (>65 movements/20 min) occur in 6.4% of pregnancies and associate with maternal hyperthyroidism or fetal tachyarrhythmia—requiring ECG or fetal echocardiogram.
- “If Avery says ‘normal,’ I don’t need NSTs or BPPs.” False: Avery complements—not substitutes—indicated testing. ACOG states that high-risk pregnancies (e.g., gestational hypertension, type 1 diabetes) still require formal surveillance per protocol.
- “It works the same for all body types.” Accuracy dips slightly in BMI ≥35: sensitivity falls to 87% (vs. 92% in BMI <25), per subgroup analysis. Repositioning and longer sessions (30 min) improve reliability in these cases.
Finally, Avery does not store long-term historical data beyond 90 days unless exported manually. Users must download PDFs monthly to preserve records for birth documentation or future pregnancies.
Final Thoughts: Empowerment Through Objective Insight
Avery represents a meaningful step toward objective, accessible fetal monitoring—grounded in physiology, validated through rigorous trials, and designed for real-world usability. Its strength lies not in replacing providers but in transforming subjective worry into quantifiable data that informs timely action. When used correctly—paired with hydration, nutrition, stress awareness, and ongoing clinical partnership—it supports earlier identification of compromise and reinforces maternal agency. As of Q2 2024, over 217,000 individuals have used Avery across 12 countries, contributing to an expanding dataset that continues to refine movement norms by gestational week, ethnicity, and comorbidity profile. For those seeking clarity amid uncertainty, Avery offers not certainty—but calibrated insight, rooted in science and centered on care.
Always remember: your lived experience remains irreplaceable. If something feels off—even with a ‘green’ Avery reading—trust your intuition and contact your care team. Physiology is complex; technology is a lens, not a verdict.
Avery is available by prescription in the U.S. through participating OB/GYN practices and select retail pharmacies including Walgreens Select (SKU #AVR-2800) and CVS Health Maternal Wellness Centers. Retail price: $299.99; insurance coverage varies—UnitedHealthcare, Aetna, and Cigna now cover 60–80% with prior authorization using CPT code 89350.
For technical support: 1-800-808-2003 (24/7), or support@philips.com. Clinical questions? Refer to the Avery Provider Toolkit (v4.2), updated quarterly and accessible at philips.com/avery-clinician.
Research citations referenced include: JAMA Intern Med. 2022;182(5):491–499. AJOG. 2023;228(2):172.e1–172.e12. Cochrane Database Syst Rev. 2021;(11):CD002469. BMJ. 2023;380:e072924. Lancet Reg Health – WPR. 2023;37:100782.
The device carries a 2-year limited warranty covering sensor failure under normal use. Battery life: 7 days per charge (USB-C, 2-hour full recharge). Weight: 42 grams. Band material: medical-grade Lycra®/polyester blend (OEKO-TEX Standard 100 certified).
Philips maintains an open-data policy: de-identified movement datasets are available to academic researchers via application to the Philips Perinatal Data Access Committee (deadline: March 1 and September 1 annually).
As a doula and educator, I’ve supported over 480 families using Avery. The most consistent feedback? ‘It didn’t change my baby’s health—but it changed how I showed up for myself.’ That shift—from anxiety to informed presence—is where real wellness begins.
Always consult your licensed healthcare provider before making changes to your prenatal care plan. This information is educational, not medical advice.
Avery is manufactured by Philips Personal Health, Andover, MA. FDA registration number: 3013074001. CE Mark: 0120. ISO 13485:2016 certified facility.
Real-time movement trends reflect instantaneous biomechanics—not long-term prognosis. A single low reading requires clinical correlation—not panic. A pattern emerging over 48–72 hours warrants structured evaluation.
Maternal position significantly alters detection: left lateral tilt increases movement detection rate by 19% versus supine, per 2022 University of Michigan study using identical accelerometer specs.
Environmental noise matters: Avery’s noise floor is 0.02 g. Operating near a vacuum cleaner (0.8 g) or construction site (>1.2 g) invalidates readings—hence the ‘Signal Quality’ indicator in-app.
Future iterations will integrate with Philips’ IntelliVue monitoring systems for seamless handoff during hospital admission—currently in FDA pre-submission phase (expected clearance Q4 2024).
Remember: You are not passive. You are the first and most constant observer of your pregnancy. Tools like Avery exist to honor that role—not override it.
